Revenue from Contract with Customer, Excluding Assessed Tax of Bionik Laboratories Corp. from 31 Dec 2019 to 31 Mar 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Summary
Bionik Laboratories Corp. quarterly and annual Revenue from Contract with Customer, Excluding Assessed Tax in USD history and change rate from 31 Dec 2019 to 31 Mar 2023.
  • Bionik Laboratories Corp. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 31 Mar 2023 was $501,114, a 162% increase year-over-year.
  • Bionik Laboratories Corp. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending 31 Mar 2023 was $1,805,202, a 42% increase year-over-year.
  • Bionik Laboratories Corp. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $1,805,202, a 42% increase from 2021.
  • Bionik Laboratories Corp. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2021 was $1,273,712, a 6.7% increase from 2020.
  • Bionik Laboratories Corp. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2020 was $1,193,430, a 45% decline from 2019.
Source SEC data
View on sec.gov
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)

Bionik Laboratories Corp. Quarterly Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2023 $1,805,202 $501,114 +$309,852 +162% 01 Jan 2023 31 Mar 2023 10-K 21 Jun 2023 2023 FY
Q4 2022 $1,495,350 $575,054 +$391,792 +214% 01 Oct 2022 31 Dec 2022 10-Q 08 Feb 2023 2023 Q3
Q3 2022 $1,103,558 $486,205 +$258,300 +113% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2022 2023 Q2
Q2 2022 $845,258 $242,829 -$428,454 -64% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2022 2022 Q1
Q1 2022 $1,273,712 $191,262 -$271,470 -59% 01 Jan 2022 31 Mar 2022 10-K 21 Jun 2023 2023 FY
Q4 2021 $1,545,182 $183,262 +$2,853 +1.6% 01 Oct 2021 31 Dec 2021 10-Q 08 Feb 2023 2023 Q3
Q3 2021 $1,542,329 $227,905 -$64,476 -22% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2023 Q2
Q2 2021 $1,606,805 $671,283 +$413,375 +160% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q1
Q1 2021 $1,193,430 $462,732 01 Jan 2021 31 Mar 2021 10-K 09 Jun 2022 2022 FY
Q4 2020 $180,409 +$22,404 +14% 01 Oct 2020 31 Dec 2020 10-Q 09 Feb 2022 2022 Q3
Q3 2020 $292,381 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2022 Q2
Q2 2020 $257,908 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2022 Q1
Q4 2019 $158,005 01 Oct 2019 31 Dec 2019 10-Q 11 Feb 2021 2020 Q3

Bionik Laboratories Corp. Annual Revenue from Contract with Customer, Excluding Assessed Tax (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $1,805,202 +$531,490 +42% 01 Apr 2022 31 Mar 2023 10-K 21 Jun 2023 2023 FY
2021 $1,273,712 +$80,282 +6.7% 01 Apr 2021 31 Mar 2022 10-K 21 Jun 2023 2023 FY
2020 $1,193,430 -$959,924 -45% 01 Apr 2020 31 Mar 2021 10-K 09 Jun 2022 2022 FY
2019 $2,153,354 01 Apr 2019 31 Mar 2020 10-K 24 Jun 2021 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.